RGNX · Regenxbio Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $170.44M | $83.33M | $90.24M | $112.72M | $470.35M | $154.57M |
| Cost of Revenue | - | $33.57M | $37.21M | $54.55M | $51.83M | $35.71M |
| Gross Profit | - | $49.76M | $53.03M | $58.18M | $418.51M | $118.85M |
| R&D | $228.30M | $208.52M | $232.27M | $242.45M | $181.44M | $166.29M |
| SG&A | $82.86M | $76.62M | $88.49M | $85.28M | $79.33M | $63.82M |
| Total Operating Expenses | $331.64M | $316.67M | $358.37M | $375.60M | $310.37M | $273.80M |
| D&A | $15.62M | $16.21M | $17.32M | $12.91M | $9.56M | $8.41M |
| Operating Income | ($161.20M) | ($233.35M) | ($268.13M) | ($262.88M) | $159.98M | ($119.23M) |
| Interest Expense | $45.01M | $12.66M | $6.86M | $23.25M | $26.28M | $771.0K |
| Income Tax | $0 | - | ($152.0K) | ($84.0K) | $13.41M | $5.24M |
| Net Income | ($193.88M) | ($227.10M) | ($263.49M) | ($280.32M) | $127.84M | ($111.25M) |
| EPS - Basic | ($3.76) | ($4.59) | ($6.02) | ($6.50) | $3.01 | ($2.98) |
| EPS - Diluted | ($3.76) | ($4.59) | ($6.02) | ($6.50) | $2.91 | ($2.98) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $34.47M | $57.53M | $34.52M | $96.95M | $345.21M | $338.43M |
| Accounts Receivable | $26.38M | $20.47M | $24.79M | $28.08M | $32.44M | $43.00M |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $21.36M | $22.80M | $22.79M | $27.21M | $11.39M | $10.62M |
| Current Assets | $281.28M | $278.00M | $334.97M | $415.98M | $518.83M | $531.20M |
| Total Assets | $453.03M | $465.99M | $573.97M | $833.27M | $1.11B | $708.16M |
| Current Liabilities | $118.09M | $103.19M | $130.27M | $130.43M | $130.47M | $81.45M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $350.30M | $206.34M | $262.23M | $317.07M | $349.61M | $330.41M |
| Stockholders' Equity | $102.73M | $259.65M | $311.74M | $516.20M | $764.30M | $377.75M |
| Retained Earnings | ($1.13B) | ($932.15M) | ($705.05M) | ($441.55M) | ($161.23M) | ($289.07M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($123.96M) | ($173.13M) | ($218.41M) | ($207.49M) | $218.88M | ($54.06M) |
| Investing Cash Flow | ($15.87M) | $103.45M | $190.94M | ($11.93M) | ($406.64M) | $122.76M |
| Financing Cash Flow | $116.77M | $92.68M | ($34.97M) | ($28.84M) | $195.25M | $200.21M |
| CapEx | $2.41M | $2.44M | $9.96M | $30.72M | $84.17M | $26.87M |
| Free Cash Flow | ($126.38M) | ($175.56M) | ($228.37M) | ($238.21M) | $134.70M | ($80.93M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | 59.7% | 58.8% | 51.6% | 89.0% | 76.9% |
| Operating margin | -94.6% | -280.0% | -297.1% | -233.2% | 34.0% | -77.1% |
| EBITDA margin | -85.4% | -260.6% | -277.9% | -221.8% | 36.0% | -71.7% |
| Net margin | -113.8% | -272.5% | -292.0% | -248.7% | 27.2% | -72.0% |
| Free cash flow margin | -74.1% | -210.7% | -253.1% | -211.3% | 28.6% | -52.4% |
| FCF / Net income | 0.65 | 0.77 | 0.87 | 0.85 | 1.05 | 0.73 |
| R&D / Revenue | 133.9% | 250.2% | 257.4% | 215.1% | 38.6% | 107.6% |
| SG&A / Revenue | 48.6% | 91.9% | 98.1% | 75.7% | 16.9% | 41.3% |
| Effective tax rate | - | - | - | - | 9.5% | - |
| Return on assets | -42.8% | -48.7% | -45.9% | -33.6% | 11.5% | -15.7% |
| Return on equity | -188.7% | -87.5% | -84.5% | -54.3% | 16.7% | -29.5% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 2.38 | 2.69 | 2.57 | 3.19 | 3.98 | 6.52 |
| Quick ratio | 2.38 | 2.69 | 2.57 | 3.19 | 3.98 | 6.52 |
| Cash ratio | 0.29 | 0.56 | 0.26 | 0.74 | 2.65 | 4.16 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -3.6x | -18.4x | -39.1x | -11.3x | 6.1x | -154.6x |
| Equity multiplier | 4.41 | 1.79 | 1.84 | 1.61 | 1.46 | 1.87 |
| Liabilities / Assets | 0.77 | 0.44 | 0.46 | 0.38 | 0.31 | 0.47 |
| Efficiency | ||||||
| Asset turnover | 0.38 | 0.18 | 0.16 | 0.14 | 0.42 | 0.22 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 56d | 90d | 100d | 91d | 25d | 102d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | 248d | 223d | 182d | 80d | 109d |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | 11.2x | - |
| P / B | 7.2x | 1.5x | 2.5x | 1.9x | 1.9x | 4.5x |
| P / S | 4.4x | 4.6x | 8.7x | 8.7x | 3.1x | 10.9x |
| EV / EBITDA | - | - | - | - | 6.4x | - |
| Growth | ||||||
| Revenue growth (YoY) | 104.5% | -7.7% | -19.9% | -76.0% | 204.3% | 338.7% |
| Revenue CAGR (3y) | 14.8% | -43.8% | -16.4% | 47.4% | 368.0% | 145.9% |
| Revenue CAGR (5y) | 2.0% | 18.8% | 81.4% | 61.1% | 152.4% | 91.0% |
| Gross profit growth (YoY) | - | -6.2% | -8.9% | -86.1% | 252.1% | 254.5% |
| Operating income growth (YoY) | 30.9% | 13.0% | -2.0% | - | - | 20.0% |
| Net income growth (YoY) | 14.6% | 13.8% | 6.0% | - | - | -17.4% |
| EPS growth (YoY) | 18.1% | 23.8% | 7.4% | - | - | -15.5% |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 28.0% | 23.1% | 4.1% | - | - | 32.2% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -60.4% | -16.7% | -39.6% | -32.5% | 102.3% | -16.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$170.44M totalLicense And Service$156.27M · 91.7%
Service$14.17M · 8.3%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-2.45
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing REGENXBIO Inc. against the 5 most active filers in the same SIC group.